{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:08:27Z","timestamp":1793394507963,"version":"4.5.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Muscle-invasive bladder cancer (MIBC) treatment depends on histological subtypes. While urothelial carcinoma (UC) benefits from novel therapies, options beyond radical cystectomy for rare subtypes such as squamous cell carcinoma (SCC) remain limited. Since we previously demonstrated ATR inhibitor (ATRi) enhanced radiation sensitivity in vitro\n                      <jats:italic>,<\/jats:italic>\n                      we aimed to further decipher the therapeutic impact of ATRi and compensatory pathways bypassing ATRi-resistance in patient-derived ex vivo cultures (PDCs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PDCs (p-SCC, p-UC,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) were established and characterized by immunohistochemistry, qPCR, and whole-exome sequencing. Independent ATRi-resistant cell models (p-SCC\n                      <jats:sup>ATRi<\/jats:sup>\n                      ) were generated through long-term ATRi treatment (Ceralasertib) and characterized by multi-dimensional profiling. Drug responses were analyzed via cell viability (IC50) and clonogenic survival assays\u2009\u00b1\u2009ionizing radiation (IR). DNA repair capacity was measured via \u03b3H2AX immunofluorescence, comet assays, qPCR, and immunoblotting. ATR siRNA knockdown and ATRi short-term studies validated the ATR-RAD51 axis. RAD51 inhibitor (RAD51i) B02 was tested in p-SCC\n                      <jats:sup>ATRi<\/jats:sup>\n                      by cell cycle analysis and\n                      <jats:italic>in ovo<\/jats:italic>\n                      tumor growth of chorioallantoic membrane (CAM) xenografts, complemented by apoptosis staining.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ATRi treatment sensitized cells to IR, reducing IC50 values up to 2.5-fold (at 8\u00a0Gy: 0.52 \u00b5M in SCC, 0.82 \u00b5M in UC). Clonogenic assays and \u03b3H2AX staining confirmed impaired DNA repair (\u03b3H2AX foci at 8\u00a0Gy: 11-fold in SCC, 15-fold in UC). In resistant p-SCC\n                      <jats:sup>ATRi<\/jats:sup>\n                      models, ATRi-adaptation triggered various compensatory and potentially epigenetic regulated DNA repair pathways, particularly homologous recombination (HR) repair involving genes like\n                      <jats:italic>BRCA1<\/jats:italic>\n                      and\n                      <jats:italic>RAD51<\/jats:italic>\n                      . Downstream consequences of functional ATR loss also affected non-DNA repair processes such as cell cycle, chromatin reorganization, and immunomodulation. As a therapeutic strategy, RAD51i overcame resistance by lowering IC50 by 40\u201380%, increasing DNA damage (2.2-fold \u03b3H2AX foci), and inducing G2\/M arrest (2.4-fold). Finally,\n                      <jats:italic>in ovo<\/jats:italic>\n                      , RAD51i significantly induced apoptosis impairing tumor growth in p-SCC\n                      <jats:sup>ATRi<\/jats:sup>\n                      xenografts by up to 37%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results propose ATR as a promising target in bladder cancer by (1) enhancing radio-sensitivity through classical ATR inhibition and (2) exploiting resistant ATRi-adaptation as a vulnerability by targeting compensatory HR repair reliance through RAD51 inhibition. These findings on the ATR\u2013HR axis suggest novel strategies to improve bladder cancer treatment and addressing therapy resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03603-4","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:04:07Z","timestamp":1765519447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting ATR offers multifaceted treatment strategies involving RAD51-mediated compensatory DNA repair in bladder cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Julia","family":"Pannhausen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Chughtai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem-Louis","family":"Y\u00fcce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lancelot","family":"Seillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel P. C.","family":"van der Vorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Andrieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Leypold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"K\u00fchnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Heilmann-Heimbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Boerries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kleger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Saar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Eble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny D.","family":"Jonigk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine T.","family":"Gaisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"3603_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540\u2013e55625.","journal-title":"Cell"},{"key":"3603_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420\u201333.","journal-title":"Eur Urol"},{"key":"3603_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","volume":"75","author":"JI Warrick","year":"2019","unstructured":"Warrick JI, et al. Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur Urol. 2019;75:18\u201322.","journal-title":"Eur Urol"},{"key":"3603_CR4","doi-asserted-by":"crossref","unstructured":"Gupta S, et al. Bladder preservation strategies in Muscle-invasive bladder cancer: recommendations from the international bladder cancer group. Eur Urol. 2025.","DOI":"10.1007\/978-3-031-68505-7_22"},{"key":"3603_CR5","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","volume":"35","author":"GS Kulkarni","year":"2017","unstructured":"Kulkarni GS, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. JCO. 2017;35:2299\u2013305.","journal-title":"JCO"},{"key":"3603_CR6","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","volume":"32","author":"RH Mak","year":"2014","unstructured":"Mak RH, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. JCO. 2014;32:3801\u20139.","journal-title":"JCO"},{"key":"3603_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijrobp.2007.06.030","volume":"70","author":"S Kotwal","year":"2008","unstructured":"Kotwal S, et al. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phy. 2008;70:456\u201363.","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"3603_CR8","first-page":"272.e1","volume":"40","author":"K Softness","year":"2022","unstructured":"Softness K, et al. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urol Oncol Semin Orig Investig. 2022;40:272.e1-272.e9.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"3603_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2022.40.6_suppl.433","volume":"40","author":"AR Zlotta","year":"2022","unstructured":"Zlotta AR, et al. Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle-invasive bladder cancer. J Clin Oncol. 2022;40:433.","journal-title":"J Clin Oncol"},{"key":"3603_CR10","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1200\/JCO.23.00725","volume":"41","author":"M Swinton","year":"2023","unstructured":"Swinton M, et al. Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer. J Clin Oncol. 2023;41:4406\u201315.","journal-title":"J Clin Oncol"},{"key":"3603_CR11","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Guidelines - Bladder Cancer. Available at https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417. (2025)."},{"key":"3603_CR12","unstructured":"European Association of Urology (EAU). EAU guidelines on muscle-invasive and metastatic bladder cancer. Available at (2025). https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer\/panel."},{"key":"3603_CR13","doi-asserted-by":"crossref","unstructured":"Murthy V, et al. Bladder Adjuvant Radiotherapy (BART): Clinical outcomes from a phase III multicenter randomized controlled trial (2025). https:\/\/amportal.astro.org\/sessions\/pl-01-21644\/bladder-adjuvant-radiotherapy-bart-clinical-outcomes-from-a-phase-iii-multicenter-randomized-109076.","DOI":"10.1016\/j.ijrobp.2025.06.1007"},{"key":"3603_CR14","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s10147-019-01409-x","volume":"24","author":"A Dotson","year":"2019","unstructured":"Dotson A, et al. Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy. Int J Clin Oncol. 2019;24:706\u201311.","journal-title":"Int J Clin Oncol"},{"key":"3603_CR15","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1016\/j.clgc.2017.07.008","volume":"15","author":"A Minato","year":"2017","unstructured":"Minato A, Fujimoto N, Kubo T. Squamous differentiation predicts poor response to cisplatin-based chemotherapy and unfavorable prognosis in urothelial carcinoma of the urinary bladder. Clin Genitourin Cancer. 2017;15:e1063-7.","journal-title":"Clin Genitourin Cancer"},{"key":"3603_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","volume":"18","author":"TW Flaig","year":"2020","unstructured":"Flaig TW, et al. Bladder Cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network: JNCCN. 2020;18:329\u201354.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"3603_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00345-019-02771-1","volume":"38","author":"X Lin","year":"2020","unstructured":"Lin X, et al. The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a meta-analysis. World J Urol. 2020;38:323\u201333.","journal-title":"World J Urol"},{"key":"3603_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-3291-8","volume-title":"Urothelial Carcinoma","author":"MJ Hoffmann","year":"2023","unstructured":"Hoffmann MJ, Gaisa NT, Nawroth R, Ecke TH. Urothelial carcinoma. Springer US; 2023."},{"key":"3603_CR19","unstructured":"Cytion. SCaBER Cells. General information. Available at https:\/\/www.cytion.com\/us\/SCaBER-Cells\/305111?utm_source=chatgpt.com. (2025)."},{"key":"3603_CR20","doi-asserted-by":"publisher","unstructured":"Chughtai AA, et al. Effective radiosensitization of bladder cancer cells by pharmacological inhibition of DNA-PK and ATR. Biomedicines 10 (2022). https:\/\/doi.org\/10.3390\/biomedicines10061277.","DOI":"10.3390\/biomedicines10061277"},{"key":"3603_CR21","doi-asserted-by":"crossref","unstructured":"Drew Y, Zenke FT, Curtin NJ. DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nat Rev Drug Discov. 2024.","DOI":"10.1038\/s41573-024-01060-w"},{"key":"3603_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 2017;66:801\u201317.","journal-title":"Mol Cell"},{"key":"3603_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"key":"3603_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf9246","volume":"8","author":"Y Pommier","year":"2016","unstructured":"Pommier Y, O\u2019Connor MJ, Bono Jde. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8:362ps17.","journal-title":"Sci Transl Med"},{"key":"3603_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01548-8","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, et al. A new wave of innovations within the DNA damage response. Signal Transduct Target Ther. 2023;8:338.","journal-title":"Signal Transduct Target Ther"},{"key":"3603_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.dnarep.2016.05.020","volume":"44","author":"GR Kidiyoor","year":"2016","unstructured":"Kidiyoor GR, Kumar A, Foiani M. ATR-mediated regulation of nuclear and cellular plasticity. DNA Repair. 2016;44:143\u201350.","journal-title":"DNA Repair"},{"key":"3603_CR27","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","volume":"18","author":"E Lecona","year":"2018","unstructured":"Lecona E, Fernandez-Capetillo O. Targeting ATR in cancer. Nat Rev Cancer. 2018;18:586\u201395.","journal-title":"Nat Rev Cancer"},{"key":"3603_CR28","unstructured":"AstraZeneca. Ceralasertib - AstraZeneca\/University of Pennsylvania - AdisInsight. Available at https:\/\/adisinsight.springer.com\/drugs\/800039325. (2025)."},{"key":"3603_CR29","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington SL, et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin Cancer Research: Official J Am Association Cancer Res. 2023;29:2800\u20137.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"3603_CR30","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","volume":"29","author":"A Ring","year":"2023","unstructured":"Ring A, et al. Olaparib and ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: results from cohort E of the plasmamatch trial (CRUK\/15\/010). Clin Cancer Research: Official J Am Association Cancer Res. 2023;29:4751\u20139.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"3603_CR31","doi-asserted-by":"publisher","first-page":"10005","DOI":"10.1200\/JCO.2025.43.16_suppl.10005","volume":"43","author":"SJ Forrest","year":"2025","unstructured":"Forrest SJ, et al. Results of a phase II trial of Olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma. JCO. 2025;43:10005.","journal-title":"JCO"},{"key":"3603_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9161","volume":"41","author":"B Besse","year":"2023","unstructured":"Besse B, et al. LATIFY: Phase 3 study of ceralasertib\u2009+\u2009durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy. JCO. 2023;41:TPS9161-TPS9161.","journal-title":"JCO"},{"key":"3603_CR33","doi-asserted-by":"publisher","unstructured":"Vendetti FP et al. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. JCI Insight 8 (2023). https:\/\/doi.org\/10.1172\/jci.insight.165615.","DOI":"10.1172\/jci.insight.165615"},{"key":"3603_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/1535-7163.MCT-16-0239","volume":"16","author":"MT Dillon","year":"2017","unstructured":"Dillon MT, et al. Radiosensitization by the ATR inhibitor AZD6738 through generation of acentric micronuclei. Mol Cancer Ther. 2017;16:25\u201334.","journal-title":"Mol Cancer Ther"},{"key":"3603_CR35","doi-asserted-by":"publisher","unstructured":"Sheng H, et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer 8 (2020). https:\/\/doi.org\/10.1136\/jitc-2019-000340.","DOI":"10.1136\/jitc-2019-000340"},{"key":"3603_CR36","first-page":"e361","volume":"120","author":"L Gong","year":"2024","unstructured":"Gong L, et al. AP97-110 combined with AZD6738 and radiotherapy sensitivity of liver cancer by inhibiting XPO1 and ATR. Int J Radiat Oncol Biol Phys. 2024;120:e361\u20132.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3603_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41523-020-00181-w","volume":"6","author":"S Guerrero Llobet","year":"2020","unstructured":"Guerrero Llobet S, et al. Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer. NPJ Breast Cancer. 2020;6:40.","journal-title":"NPJ Breast Cancer"},{"key":"3603_CR38","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nsmb.2076","volume":"18","author":"LI Toledo","year":"2011","unstructured":"Toledo LI, et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol. 2011;18:721\u20137.","journal-title":"Nat Struct Mol Biol"},{"key":"3603_CR39","doi-asserted-by":"publisher","first-page":"9693","DOI":"10.1158\/0008-5472.CAN-10-2286","volume":"70","author":"O Gilad","year":"2010","unstructured":"Gilad O, et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 2010;70:9693\u2013702.","journal-title":"Cancer Res"},{"key":"3603_CR40","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/nsmb.2189","volume":"18","author":"M Murga","year":"2011","unstructured":"Murga M, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol. 2011;18:1331\u20135.","journal-title":"Nat Struct Mol Biol"},{"key":"3603_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41389-020-00270-2","volume":"9","author":"YP Kok","year":"2020","unstructured":"Kok YP, et al. Overexpression of Cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors. Oncogenesis. 2020;9:88.","journal-title":"Oncogenesis"},{"key":"3603_CR42","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1158\/0008-5472.CAN-16-3389","volume":"77","author":"R Buisson","year":"2017","unstructured":"Buisson R, Lawrence MS, Benes CH, Zou L. APOBEC3A and APOBEC3B activities render cancer cells susceptible to ATR inhibition. Cancer Res. 2017;77:4567\u201378.","journal-title":"Cancer Res"},{"key":"3603_CR43","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.trecan.2018.09.007","volume":"4","author":"OL Kantidze","year":"2018","unstructured":"Kantidze OL, Velichko AK, Luzhin AV, Petrova NV, Razin SV. Synthetically lethal interactions of ATM, ATR, and DNA-PKcs. Trends Cancer. 2018;4:755\u201368.","journal-title":"Trends Cancer"},{"key":"3603_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19:107.","journal-title":"Mol Cancer"},{"key":"3603_CR45","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","volume":"38","author":"C Wang","year":"2019","unstructured":"Wang C, et al. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. Oncogene. 2019;38:2451\u201363.","journal-title":"Oncogene"},{"key":"3603_CR46","doi-asserted-by":"publisher","first-page":"190156","DOI":"10.1098\/rsob.190156","volume":"9","author":"N Hustedt","year":"2019","unstructured":"Hustedt N, et al. A consensus set of genetic vulnerabilities to ATR inhibition. Open Biol. 2019;9:190156.","journal-title":"Open Biol"},{"key":"3603_CR47","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2020.05.040","volume":"182","author":"M Olivieri","year":"2020","unstructured":"Olivieri M, et al. A genetic map of the response to DNA damage in human cells. Cell. 2020;182:481-496.e21.","journal-title":"Cell"},{"key":"3603_CR48","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1016\/j.jmb.2017.07.020","volume":"429","author":"C Mayor-Ruiz","year":"2017","unstructured":"Mayor-Ruiz C, Dominguez O, Fernandez-Capetillo O. Trapseq: an RNA sequencing-based pipeline for the identification of gene-trap insertions in mammalian cells. J Mol Biol. 2017;429:2780\u20139.","journal-title":"J Mol Biol"},{"key":"3603_CR49","doi-asserted-by":"publisher","first-page":"8665","DOI":"10.1093\/nar\/gkab628","volume":"49","author":"RL Lloyd","year":"2021","unstructured":"Lloyd RL, et al. Loss of cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress. Nucleic Acids Res. 2021;49:8665\u201383.","journal-title":"Nucleic Acids Res"},{"key":"3603_CR50","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1002\/1878-0261.13224","volume":"16","author":"JS Baxter","year":"2022","unstructured":"Baxter JS, Zatreanu D, Pettitt SJ, Lord CJ. Resistance to DNA repair inhibitors in cancer. Mol Oncol. 2022;16:3811\u201327.","journal-title":"Mol Oncol"},{"key":"3603_CR51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2016.03.006","volume":"62","author":"S Ruiz","year":"2016","unstructured":"Ruiz S, et al. A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors. Mol Cell. 2016;62:307\u201313.","journal-title":"Mol Cell"},{"key":"3603_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13578-016-0134-2","volume":"7","author":"A Palovcak","year":"2017","unstructured":"Palovcak A, Liu W, Yuan F, Zhang Y. Maintenance of genome stability by fanconi anemia proteins. Cell Biosci. 2017;7:8.","journal-title":"Cell Biosci"},{"key":"3603_CR53","doi-asserted-by":"publisher","first-page":"10502","DOI":"10.1074\/jbc.TM118.000371","volume":"293","author":"J Her","year":"2018","unstructured":"Her J, Bunting SF. How cells ensure correct repair of DNA double-strand breaks. J Biol Chem. 2018;293:10502\u201311.","journal-title":"J Biol Chem"},{"key":"3603_CR54","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1038\/onc.2014.276","volume":"34","author":"M Krajewska","year":"2015","unstructured":"Krajewska M, et al. ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Oncogene. 2015;34:3474\u201381.","journal-title":"Oncogene"},{"key":"3603_CR55","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1158\/0008-5472.CAN-17-1754","volume":"77","author":"E Metzger","year":"2017","unstructured":"Metzger E, et al. KDM4 inhibition targets breast cancer stem-like cells. Cancer Res. 2017;77:5900\u201312.","journal-title":"Cancer Res"},{"key":"3603_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00040","volume":"4","author":"M McDermott","year":"2014","unstructured":"McDermott M, et al. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol. 2014;4:40.","journal-title":"Front Oncol"},{"key":"3603_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00579-3","volume":"13","author":"MK Melzer","year":"2024","unstructured":"Melzer MK, et al. Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction - feasibility and real world experience. Exp Hematol Oncol. 2024;13:112.","journal-title":"Exp Hematol Oncol"},{"key":"3603_CR58","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"The Cancer Genome Atlas Research Network","year":"2014","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315\u201322.","journal-title":"Nature"},{"key":"3603_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111859","volume":"41","author":"TN Clinton","year":"2022","unstructured":"Clinton TN, et al. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep. 2022;41:111859.","journal-title":"Cell Rep"},{"key":"3603_CR60","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"3603_CR61","doi-asserted-by":"publisher","first-page":"6856","DOI":"10.1038\/s41388-020-01465-y","volume":"39","author":"M Rose","year":"2020","unstructured":"Rose M, et al. EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer. Oncogene. 2020;39:6856\u201370.","journal-title":"Oncogene"},{"key":"3603_CR62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-4939-7234-0_4","volume":"1655","author":"M Rose","year":"2018","unstructured":"Rose M, Gaisa NT. Immunohistochemical analysis of urothelial carcinoma tissues for proliferation and differentiation markers. Methods Mol Biology (Clifton N J). 2018;1655:43\u201352.","journal-title":"Methods Mol Biology (Clifton N J)"},{"key":"3603_CR63","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE. Vorschlag zur einheitlichen Definition eines immunreaktiven Score (IRS) f\u00fcr den immunhistochemischen Ostrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe. 1987;8:138\u201340.","journal-title":"Pathologe"},{"key":"3603_CR64","doi-asserted-by":"publisher","first-page":"63","DOI":"10.12688\/f1000research.16665.2","volume":"9","author":"M Garcia","year":"2020","unstructured":"Garcia M, et al. Sarek: a portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Res. 2020;9:63.","journal-title":"F1000Res"},{"key":"3603_CR65","doi-asserted-by":"publisher","DOI":"10.1093\/nargab\/lqae031","volume":"6","author":"F Hanssen","year":"2024","unstructured":"Hanssen F, et al. Scalable and efficient DNA sequencing analysis on different compute infrastructures aiding variant discovery. NAR Genom Bioinform. 2024;6:lqae031.","journal-title":"NAR Genom Bioinform"},{"key":"3603_CR66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, et al. The ensembl variant effect predictor. Genome Biol. 2016;17:122.","journal-title":"Genome Biol"},{"key":"3603_CR67","doi-asserted-by":"publisher","unstructured":"CIO-ABCD, Horny K, Seillier L, H\u00f6lscher F, Basitta P. variantinterpretation (v1.0.0). Zenodo 2023. https:\/\/doi.org\/10.5281\/ZENODO.10036356.","DOI":"10.5281\/ZENODO.10036356"},{"key":"3603_CR68","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic M, et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 2024;52:D672\u20138.","journal-title":"Nucleic Acids Res"},{"key":"3603_CR69","doi-asserted-by":"publisher","unstructured":"Kasper Daniel Hansen. IlluminaHumanMethylationEPICmanifest (Bioconductor, 2017). https:\/\/doi.org\/10.18129\/B9.BIOC.ILLUMINAHUMANMETHYLATIONEPICMANIFEST.","DOI":"10.18129\/B9.BIOC.ILLUMINAHUMANMETHYLATIONEPICMANIFEST"},{"key":"3603_CR70","first-page":"1363","volume":"30","author":"MJ Aryee","year":"2014","unstructured":"Aryee MJ, et al. Minfi: a flexible and comprehensive bioconductor package for the analysis of infinium DNA methylation microarrays. Bioinf (Oxford England). 2014;30:1363\u20139.","journal-title":"Bioinf (Oxford England)"},{"key":"3603_CR71","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1158\/0008-5472.CAN-21-4335","volume":"82","author":"PC O'Leary","year":"2022","unstructured":"O\u2019Leary PC, et al. Resistance to ATR inhibitors is mediated by loss of the nonsense-mediated decay factor UPF2. Cancer Res. 2022;82:3950\u201361.","journal-title":"Cancer Res"},{"key":"3603_CR72","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"3603_CR73","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/bioinformatics\/bti525","volume":"21","author":"S Durinck","year":"2005","unstructured":"Durinck S, et al. BioMart and bioconductor: a powerful link between biological databases and microarray data analysis. Bioinf (Oxford England). 2005;21:3439\u201340.","journal-title":"Bioinf (Oxford England)"},{"key":"3603_CR74","first-page":"3151","volume":"35","author":"J Rainer","year":"2019","unstructured":"Rainer J, Gatto L, Weichenberger CX. Ensembldb: an R package to create and use Ensembl-based annotation resources. Bioinf (Oxford England). 2019;35:3151\u20133.","journal-title":"Bioinf (Oxford England)"},{"key":"3603_CR75","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang L-G, Han Y, He Q-Y. Clusterprofiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"3603_CR76","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"3603_CR77","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nprot.2013.092","volume":"8","author":"H Mi","year":"2013","unstructured":"Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc. 2013;8:1551\u201366.","journal-title":"Nat Protoc"},{"key":"3603_CR78","first-page":"2114","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinf (Oxford England). 2014;30:2114\u201320.","journal-title":"Bioinf (Oxford England)"},{"key":"3603_CR79","first-page":"15","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinf (Oxford England). 2013;29:15\u201321.","journal-title":"Bioinf (Oxford England)"},{"key":"3603_CR80","unstructured":"R Core Team. R: A Language and environment for statistical computing. R Foundation for Statistical Computing; 2024. https:\/\/www.r-rproject.org."},{"key":"3603_CR81","first-page":"139","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. EdgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinf (Oxford England). 2010;26:139\u201340.","journal-title":"Bioinf (Oxford England)"},{"key":"3603_CR82","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"3603_CR83","doi-asserted-by":"publisher","unstructured":"Chirumamilla CS, et al. Profiling activity of cellular kinases in migrating T-cells. Methods Mol Biol. 2019;1930, 99\u2013113. https:\/\/doi.org\/10.1007\/978-1-4939-9036-8_13.","DOI":"10.1007\/978-1-4939-9036-8_13"},{"key":"3603_CR84","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, et al. ClusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2:100141.","journal-title":"Innovation"},{"key":"3603_CR85","first-page":"608","volume":"31","author":"G Yu","year":"2015","unstructured":"Yu G, Wang L-G, Yan G-R, He Q-Y. DOSE: an R\/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinf (Oxford England). 2015;31:608\u20139.","journal-title":"Bioinf (Oxford England)"},{"key":"3603_CR86","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1039\/C5MB00663E","volume":"12","author":"G Yu","year":"2016","unstructured":"Yu G, He Q-Y. ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst. 2016;12:477\u20139.","journal-title":"Mol Biosyst"},{"key":"3603_CR87","doi-asserted-by":"publisher","first-page":"13443","DOI":"10.1038\/s41598-025-96419-3","volume":"15","author":"J Pannhausen","year":"2025","unstructured":"Pannhausen J, et al. Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer. Sci Rep. 2025;15:13443.","journal-title":"Sci Rep"},{"key":"3603_CR88","first-page":"544.e11","volume":"35","author":"MA Skowron","year":"2017","unstructured":"Skowron MA, et al. Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma. Urol Oncol Semin Orig Investig. 2017;35:544.e11-544.e23.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"3603_CR89","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3233\/BLC-150037","volume":"2","author":"SP Lerner","year":"2016","unstructured":"Lerner SP, et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer (Amsterdam Netherlands). 2016;2:37\u201347.","journal-title":"Bladder Cancer (Amsterdam Netherlands)"},{"key":"3603_CR90","unstructured":"Baillargeon M. Mastering the fight against drug resistance: how to choose and use the right models. Available at (2025). https:\/\/blog.crownbio.com\/how-to-choose-and-use-the-right-drug-resistance-models."},{"key":"3603_CR91","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.15099","volume":"11","author":"I Takan","year":"2023","unstructured":"Takan I, Karak\u00fclah G, Louka A, Pavlopoulou A. In the light of evolution:\" keratins as exceptional tumor biomarkers. PeerJ. 2023;11:e15099.","journal-title":"PeerJ"},{"key":"3603_CR92","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/path.6207","volume":"262","author":"J Thorlacius-Ussing","year":"2024","unstructured":"Thorlacius-Ussing J, et al. The collagen landscape in cancer: profiling collagens in tumors and in circulation reveals novel markers of cancer-associated fibroblast subtypes. J Pathol. 2024;262:22\u201336.","journal-title":"J Pathol"},{"key":"3603_CR93","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/carcin\/bgt375","volume":"35","author":"M Rose","year":"2014","unstructured":"Rose M, et al. Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours. Carcinogenesis. 2014;35:727\u201336.","journal-title":"Carcinogenesis"},{"key":"3603_CR94","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-017-0610-2","volume":"16","author":"M Rose","year":"2017","unstructured":"Rose M, et al. ITIH5 mediates epigenetic reprogramming of breast cancer cells. Mol Cancer. 2017;16:44.","journal-title":"Mol Cancer"},{"key":"3603_CR95","doi-asserted-by":"publisher","unstructured":"Rose M, et al. The ECM modulator ITIH5 affects cell adhesion, motility and chemotherapeutic response of basal\/squamous-like (BASQ) bladder cancer cells. Cells. 2021;10. https:\/\/doi.org\/10.3390\/cells10051038.","DOI":"10.3390\/cells10051038"},{"key":"3603_CR96","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1080\/10985549.2024.2408016","volume":"44","author":"SN Cullati","year":"2024","unstructured":"Cullati SN, et al. The DNA damage repair function of fission yeast CK1 involves targeting Arp8, a subunit of the INO80 chromatin remodeling complex. Mol Cell Biol. 2024;44:562\u201376.","journal-title":"Mol Cell Biol"},{"key":"3603_CR97","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1038\/sj.emboj.7600469","volume":"23","author":"Y Aylon","year":"2004","unstructured":"Aylon Y, Liefshitz B, Kupiec M. The CDK regulates repair of double-strand breaks by homologous recombination during the cell cycle. EMBO J. 2004;23:4868\u201375.","journal-title":"EMBO J"},{"key":"3603_CR98","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1074\/mcp.M500327-MCP200","volume":"5","author":"Y-C Du","year":"2006","unstructured":"Du Y-C, et al. The dynamic alterations of H2AX complex during DNA repair detected by a proteomic approach reveal the critical roles of Ca2+\/Calmodulin in the ionizing radiation-induced cell cycle arrest. Mol Cell Proteom. 2006;5:1033\u201344.","journal-title":"Mol Cell Proteom"},{"key":"3603_CR99","doi-asserted-by":"publisher","unstructured":"Mohammadian Gol T, Rodemann HP, Dittmann K. Depletion of Akt1 and Akt2 impairs the repair of radiation-induced DNA double strand breaks via homologous recombination. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20246316.","DOI":"10.3390\/ijms20246316"},{"key":"3603_CR100","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a002279","volume":"2","author":"H Wang","year":"2010","unstructured":"Wang H, et al. ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harb Perspect Biol. 2010;2:a002279.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3603_CR101","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0167-5699(99)01574-1","volume":"21","author":"M Turner","year":"2000","unstructured":"Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today. 2000;21:148\u201354.","journal-title":"Immunol Today"},{"key":"3603_CR102","doi-asserted-by":"publisher","first-page":"690","DOI":"10.2174\/156802609789044443","volume":"9","author":"N Sahu","year":"2009","unstructured":"Sahu N, August A. ITK inhibitors in inflammation and immune-mediated disorders. Curr Top Med Chem. 2009;9:690\u2013703.","journal-title":"Curr Top Med Chem"},{"key":"3603_CR103","doi-asserted-by":"publisher","unstructured":"Hsu W-C, et al. CSF-1 overexpression predicts poor prognosis in upper tract urothelial carcinomas. Disease markers. 2019;2724948. https:\/\/doi.org\/10.1155\/2019\/2724948.","DOI":"10.1155\/2019\/2724948"},{"key":"3603_CR104","doi-asserted-by":"publisher","unstructured":"Hong H, Benveniste EN. The immune regulatory role of protein kinase CK2 and its implications for treatment of cancer. Biomedicines. 2021;9. https:\/\/doi.org\/10.3390\/biomedicines9121932.","DOI":"10.3390\/biomedicines9121932"},{"key":"3603_CR105","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-981-13-9367-9_10","volume":"1172","author":"MC Mulero","year":"2019","unstructured":"Mulero MC, Huxford T, Ghosh G. NF-\u03baB, I\u03baB, and IKK: integral components of immune system signaling. Adv Exp Med Biol. 2019;1172:207\u201326.","journal-title":"Adv Exp Med Biol"},{"key":"3603_CR106","doi-asserted-by":"publisher","unstructured":"Scheffler L. The role of Raf-1 and B-Raf in B cell activation, differentation, and tumorigenesis in mice. LMU M\u00fcnchen. 2023. https:\/\/doi.org\/10.5282\/EDOC.32776.","DOI":"10.5282\/EDOC.32776"},{"key":"3603_CR107","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Therapy. 2023;8:69.","journal-title":"Signal Transduct Target Therapy"},{"key":"3603_CR108","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1038\/s41467-020-18580-9","volume":"11","author":"GR Kidiyoor","year":"2020","unstructured":"Kidiyoor GR, et al. ATR is essential for preservation of cell mechanics and nuclear integrity during interstitial migration. Nat Commun. 2020;11:4828.","journal-title":"Nat Commun"},{"key":"3603_CR109","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","volume":"30","author":"B Besse","year":"2024","unstructured":"Besse B, et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med. 2024;30:716\u201329.","journal-title":"Nat Med"},{"key":"3603_CR110","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctro.2018.06.001","volume":"12","author":"MT Dillon","year":"2018","unstructured":"Dillon MT, et al. A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clin Translational Radiation Oncol. 2018;12:16\u201320.","journal-title":"Clin Translational Radiation Oncol"},{"key":"3603_CR111","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/cddis.2012.181","volume":"3","author":"E Fokas","year":"2012","unstructured":"Fokas E, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012;3:e441.","journal-title":"Cell Death Dis"},{"key":"3603_CR112","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/mc.23384","volume":"61","author":"P Karukonda","year":"2022","unstructured":"Karukonda P, Odhiambo D, Mowery YM. Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma. Mol Carcinog. 2022;61:225\u201338.","journal-title":"Mol Carcinog"},{"key":"3603_CR113","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.urology.2006.08.1107","volume":"69","author":"H Abol-Enein","year":"2007","unstructured":"Abol-Enein H, Kava BR, Carmack AJK. Nonurothelial cancer of the bladder. Urology. 2007;69:93\u2013104.","journal-title":"Urology"},{"key":"3603_CR114","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/cjp2.261","volume":"8","author":"CD Hurst","year":"2022","unstructured":"Hurst CD, et al. Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for OSMR and YAP signalling. J Pathol Clin Res. 2022;8:279\u201393.","journal-title":"J Pathol Clin Res"},{"key":"3603_CR115","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1038\/onc.2010.624","volume":"30","author":"N Sangster-Guity","year":"2011","unstructured":"Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F. ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene. 2011;30:2526\u201333.","journal-title":"Oncogene"},{"key":"3603_CR116","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper PM, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011;7:428\u201330.","journal-title":"Nat Chem Biol"},{"key":"3603_CR117","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1080\/15384101.2015.1063290","volume":"14","author":"P Kapoor","year":"2015","unstructured":"Kapoor P, Shen X. SWI\/SNF chromatin remodeling complex regulates a non-chromatin substrate. Cell Cycle. 2015;14:2379\u201380.","journal-title":"Cell Cycle"},{"key":"3603_CR118","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1021\/acschembio.0c00312","volume":"15","author":"EJ Chory","year":"2020","unstructured":"Chory EJ, et al. Chemical inhibitors of a selective SWI\/SNF function synergize with ATR inhibition in cancer cell killing. ACS Chem Biol. 2020;15:1685\u201396.","journal-title":"ACS Chem Biol"},{"key":"3603_CR119","doi-asserted-by":"publisher","unstructured":"Mavroeidi D, et al. Targeting ATR pathway in solid tumors: evidence of improving therapeutic outcomes. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms25052767.","DOI":"10.3390\/ijms25052767"},{"key":"3603_CR120","doi-asserted-by":"publisher","first-page":"eabl9330","DOI":"10.1126\/sciimmunol.abl9330","volume":"7","author":"RC-E Hsieh","year":"2022","unstructured":"Hsieh RC-E, et al. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol. 2022;7:eabl9330.","journal-title":"Sci Immunol"},{"key":"3603_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun S-C. NF-\u03baB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023-.","journal-title":"Signal Transduct Target Ther"},{"key":"3603_CR122","doi-asserted-by":"publisher","first-page":"76534","DOI":"10.18632\/oncotarget.12266","volume":"7","author":"J Murai","year":"2016","unstructured":"Murai J, et al. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget. 2016;7:76534\u201350.","journal-title":"Oncotarget"},{"key":"3603_CR123","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11:3726.","journal-title":"Nat Commun"},{"key":"3603_CR124","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","volume":"80","author":"S Rafiei","year":"2020","unstructured":"Rafiei S, et al. ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer. Cancer Res. 2020;80:2094\u2013100.","journal-title":"Cancer Res"},{"key":"3603_CR125","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","volume":"39","author":"RL Lloyd","year":"2020","unstructured":"Lloyd RL, et al. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 2020;39:4869\u201383.","journal-title":"Oncogene"},{"key":"3603_CR126","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920974201","volume":"12","author":"R Ali","year":"2020","unstructured":"Ali R, et al. XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. Ther Adv Med Oncol. 2020;12:1758835920974201.","journal-title":"Ther Adv Med Oncol"},{"key":"3603_CR127","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejmech.2015.04.021","volume":"96","author":"J Zhu","year":"2015","unstructured":"Zhu J, et al. Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors. Eur J Med Chem. 2015;96:196\u2013208.","journal-title":"Eur J Med Chem"},{"key":"3603_CR128","doi-asserted-by":"publisher","unstructured":"Shkundina IS, et al. New RAD51 inhibitors to target homologous recombination in human cells. Genes. 2021;12. https:\/\/doi.org\/10.3390\/genes12060920.","DOI":"10.3390\/genes12060920"},{"key":"3603_CR129","doi-asserted-by":"publisher","first-page":"7347","DOI":"10.1093\/nar\/gks353","volume":"40","author":"B Budke","year":"2012","unstructured":"Budke B, et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res. 2012;40:7347\u201357.","journal-title":"Nucleic Acids Res"},{"key":"3603_CR130","doi-asserted-by":"publisher","first-page":"zcaa024","DOI":"10.1093\/narcan\/zcaa024","volume":"2","author":"MK Grundy","year":"2020","unstructured":"Grundy MK, Buckanovich RJ, Bernstein KA. Regulation and pharmacological targeting of RAD51 in cancer. NAR Cancer. 2020;2:zcaa024.","journal-title":"NAR Cancer"},{"key":"3603_CR131","doi-asserted-by":"publisher","unstructured":"Thy S, et al. Epigenetic treatment of urothelial carcinoma cells sensitizes to cisplatin chemotherapy and PARP inhibitor treatment. Cancers. 2021; 13. https:\/\/doi.org\/10.3390\/cancers13061376.","DOI":"10.3390\/cancers13061376"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03603-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:27:08Z","timestamp":1781627228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03603-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3603"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03603-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients gave written informed consent, and experiments followed the regulations of the RWTH centralized Biomaterial Bank (RWTH cBMB) and the Declaration of Helsinki. This was approved by the Institutional Ethical Review Board of the Medical Faculty of RWTH Aachen University (EK 268\/21, EK 206\/09 study numbers 199 and 311).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}